journal
https://read.qxmd.com/read/38480664/correction-to-the-effect-of-pcsk9-inhibitors-on-ldl-c-target-achievement-in-patients-with-homozygous-familial-hypercholesterolemia-a-retrospective-cohort-analysis
#41
Awad Alshahrani, Naji Kholaif, Mutaz Al-Khnifsawi, Hawazen Zarif, Moeber Mahzari
No abstract text is available yet for this article.
March 13, 2024: Advances in Therapy
https://read.qxmd.com/read/38480663/correction-to-presto-2-an-international-survey-to-evaluate-patients-injection-experiences-with-the-latest-devices-formulations-of-long-acting-somatostatin-analog-therapies-for-neuroendocrine-tumors-or-acromegaly
#42
Dermot O'Toole, Pamela L Kunz, Susan M Webb, Grace Goldstein, Sheila Khawaja, Mark McDonnell, Sandra Boiziau, Delphine Gueguen, Aude Houchard, Antonio Ribeiro-Oliveira, Ally Prebtani
No abstract text is available yet for this article.
March 13, 2024: Advances in Therapy
https://read.qxmd.com/read/38480662/correction-to-comparative-efficacy-durability-and-safety-of-faricimab-in-the-treatment-of-diabetic-macular-edema-a-systematic-literature-review-and-network-meta-analysis
#43
Claire Watkins, Tatiana Paulo, Christian Bührer, Nancy M Holekamp, Marloes Bagijn
No abstract text is available yet for this article.
March 13, 2024: Advances in Therapy
https://read.qxmd.com/read/38480661/adverse-drug-events-observed-with-the-newly-approved-remimazolam-in-comparison-to-propofol-for-general-anesthesia-in-patients-undergoing-surgery-a-meta-analysis
#44
JOURNAL ARTICLE
Lidan Huang, Hong Liu, Xue Zou, Jiawang Ding, Song Tao
INTRODUCTION: Developments in anesthetic pharmacology have been aiming at minimizing physiological disturbance in addition to maintaining and improving titrateability, recovery profile, and patient experience. Remimazolam, a GABAAlpha receptor agonist, is a new intravenous anesthetic agent which has recently been approved for use. This analysis aimed to systematically compare the adverse drug events reported with the newly approved remimazolam in comparison to propofol for general anesthesia (GA) in patients undergoing surgery...
March 13, 2024: Advances in Therapy
https://read.qxmd.com/read/38480660/perioperative-and-long-term-outcomes-in-patients-undergoing-synchronous-carotid-endarterectomy-and-coronary-artery-bypass-grafting-a-single-center-experience
#45
JOURNAL ARTICLE
Paimann Nawrozi, Thomas Ratschiller, Wolfgang Schimetta, Gregor Gierlinger, Markus Pirklbauer, Hannes Müller, Andreas Zierer
INTRODUCTION: Patients requiring coronary artery bypass grafting (CABG) and carotid endarterectomy (CEA) can be managed with staged (CEA before CABG), reverse staged (CABG before CEA) or synchronous treatment. This single-center retrospective study evaluated the outcomes in patients undergoing planned synchronous CEA and CABG. METHODS: Between 2000 and 2020 a total of 185 patients with symptomatic triple-vessel or left main coronary artery disease associated with 70-99% asymptomatic or 50-99% symptomatic uni- or bilateral internal carotid artery (ICA) stenosis underwent synchronous CEA and CABG at our institution...
March 13, 2024: Advances in Therapy
https://read.qxmd.com/read/38467985/comparison-of-healthcare-costs-for-women-with-treated-versus-untreated-vasomotor-symptoms-due-to-menopause
#46
JOURNAL ARTICLE
Aki Shiozawa, Shayna Mancuso, Christopher Young, Jennifer Friderici, Summer Tran, Helen M Trenz
INTRODUCTION: The study objective was to estimate all-cause healthcare resource utilization (HCRU) and medical and pharmacy costs for women with treated versus untreated vasomotor symptoms (VMS) due to menopause. METHODS: A retrospective study was conducted using US claims data from Optum Research Database (study period: January 1, 2012-February 29, 2020). Women aged 40-63 years with a VMS diagnosis claim and ≥ 12 and ≥ 18 months of continuous enrollment during baseline and follow-up periods, respectively, were included...
March 11, 2024: Advances in Therapy
https://read.qxmd.com/read/38466559/relevance-of-adalimumab-product-attributes-to-patient-experience-in-the-biosimilar-era-a-narrative-review
#47
REVIEW
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin Wells
Adalimumab (ADL, Humira® , reference product), an anti-TNF-α biologic, has transformed the treatment of chronic, immune-mediated inflammatory diseases. However, the high cost of ADL therapy has driven the development of more affordable ADL biosimilars, agents with no clinically meaningful differences from the reference product. This review summarizes the product attributes of reference ADL and the nine ADL biosimilars approved and available in the USA in relation to patient experience of injection-site pain (ISP)...
March 11, 2024: Advances in Therapy
https://read.qxmd.com/read/38466558/the-humanistic-and-economic-burden-associated-with-major-depressive-disorder-a-retrospective-cross-sectional-analysis
#48
JOURNAL ARTICLE
Larry Culpepper, Ashley Martin, Nadia Nabulsi, Mousam Parikh
INTRODUCTION: Major depressive disorder (MDD) is a debilitating and costly condition. This analysis characterized the health-related quality of life (HRQoL), health care resource utilization (HCRU), and costs between patients with versus without MDD, and across MDD severity levels. METHODS: The 2019 National Health and Wellness Survey was used to identify adults with MDD, who were stratified by disease severity (minimal/mild, moderate, moderately severe, severe), and those without MDD...
March 11, 2024: Advances in Therapy
https://read.qxmd.com/read/38460107/efficacy-and-safety-of-transitioning-to-lemborexant-from-z-drug-suvorexant-and-ramelteon-in-japanese-insomnia-patients-an-open-label-multicenter-study
#49
JOURNAL ARTICLE
Motohiro Ozone, Susumu Hirota, Yu Ariyoshi, Kenichi Hayashida, Azusa Ikegami, Mitsunari Habukawa, Hayato Ohshima, Daisuke Harada, Hiroshi Hiejima, Nozomu Kotorii, Kenta Murotani, Takehiro Taninaga, Naohisa Uchimura
INTRODUCTION: For patients with chronic insomnia, conventional therapy may not always provide satisfactory efficacy and safety. Thus, switching to an alternative therapeutic agent can be explored. However, there is a lack of prospective studies evaluating the effectiveness of such changes. This prospective, non-randomized, open-label, interventional, multicenter study assessed whether Japanese patients with chronic insomnia dissatisfied with treatment could transition directly to lemborexant (LEM) from four cohorts-non-benzodiazepine sedative-hypnotic (zolpidem, zopiclone, or eszopiclone) monotherapy, dual orexin receptor antagonist (suvorexant) monotherapy, suvorexant + benzodiazepine receptor agonists (BZRAs), and melatonin receptor agonist (ramelteon) combination...
March 9, 2024: Advances in Therapy
https://read.qxmd.com/read/38443651/left-atrial-strain-insights-in-atrial-fibrillation-and-the-interplay-with-metabolic-syndrome
#50
JOURNAL ARTICLE
Hyun-Jin Kim, Hyun-Sun Kim
INTRODUCTION: Understanding the interplay between metabolic syndrome and left atrial (LA) function is crucial, especially in patients newly diagnosed with atrial fibrillation (AF). We evaluated the association between subclinical atrial function and metabolic syndrome in patients diagnosed with new-onset AF. METHODS: A retrospective analysis was conducted on 220 patients, aged between 20 and 100 years, who were newly diagnosed with AF. These patients were divided into two groups based on the presence or absence of metabolic syndrome...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38443650/increased-nasal-blimp1%C3%A2-%C3%A2-treg-cells-after-sublingual-immunotherapy-reflect-the-efficacy-of-treatment-in-allergic-rhinitis
#51
JOURNAL ARTICLE
Yue Pan, Xinxin Zhang, Huanting Geng, Yan Yu, Jianyong Liu, Menglin Li, Huijun Yang, Yifang Yuan, Yao Xu, Yujia Wu, Geping Wu, Xingkai Ma, Lei Cheng
INTRODUCTION: Allergen-specific immunotherapy (AIT) plays a pivotal role in altering the immune status and tissue responses in allergic rhinitis (AR). This study focuses on the impact of sublingual immunotherapy (SLIT) involving dust mite drops, exploring the modulation of regulatory T cells (Treg) and their specific marker, BLIMP1, in the nasal mucosa. METHODS: Immune cells were isolated from nasal lavage fluid of patients with AR undergoing SLIT (n = 94)...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38443649/incidence-and-costs-of-clinically-significant-events-with-systemic-therapy-in-patients-with-unresectable-hepatocellular-carcinoma-a-retrospective-cohort-study
#52
JOURNAL ARTICLE
Daniel J Simmons, Stephen J Valerio, Darren S Thomas, Marcus J Healey, Zhuoxin Jiang, Jesica M Levingston Mac Leod, Yian Lin, Janvi Sah
INTRODUCTION: Systemic therapies have been associated with clinically significant events (CSEs) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the incidence of CSEs (bleeding, clotting, encephalopathy, and portal hypertension), and their impact on healthcare resource utilization (HCRU) and costs, in patients with uHCC treated with first-line (1L) atezolizumab plus bevacizumab (A + B), lenvatinib (LEN), or sorafenib (SOR) in the USA. METHODS: A retrospective cohort study was performed using medical/pharmacy claims from Optum® Clinformatics® Data Mart...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38443648/study-design-of-a-phase-2-3-randomized-controlled-trial-of-dupilumab-in-adults-with-bullous-pemphigoid-liberty-bp-adept
#53
JOURNAL ARTICLE
Dédée F Murrell, Pascal Joly, Victoria P Werth, Hideyuki Ujiie, Margitta Worm, Aaron R Mangold, Elena Avetisova, Jennifer Maloney, Elizabeth Laws, Eric Mortensen, Ariane Dubost-Brama, Arsalan Shabbir
BACKGROUND: Bullous pemphigoid (BP) is a rare, autoimmune, blistering skin disease associated with high disease burden, profoundly decreased quality of life and increased morbidity. Emerging evidence supports an important role for type 2 inflammation in disease pathogenesis. Current management relies on topical and/or systemic corticosteroids, non-selective immunosuppressants and antibiotics with anti-inflammatory properties, which are all limited by side effects and toxicities. Therefore, targeted, efficacious and safe therapies are needed...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38443647/an-update-on-stiripentol-mechanisms-of-action-a-narrative-review
#54
REVIEW
Alexandre Bacq, Antoine Depaulis, Vincent Castagné, Marie-Emmanuelle Le Guern, Elaine C Wirrell, Marc Verleye
Stiripentol (Diacomit® ) (STP) is an orally active antiseizure medication (ASM) indicated as adjunctive therapy, for the treatment of seizures associated with Dravet syndrome (DS), a severe form of childhood epilepsy, in conjunction with clobazam and, in some regions valproic acid. Since the discovery of STP, several mechanisms of action (MoA) have been described that may explain its specific effect on seizures associated with DS. STP is mainly considered as a potentiator of gamma-aminobutyric acid (GABA) neurotransmission: (i) via uptake blockade, (ii) inhibition of degradation, but also (iii) as a positive allosteric modulator of GABAA receptors, especially those containing α3 and δ subunits...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38443646/patient-and-clinician-perspectives-to-create-a-better-future-for-chronic-kidney-disease-we-need-to-talk-about-our-kidneys
#55
JOURNAL ARTICLE
Pamela R Kushner, Jane DeMeis, Petrina Stevens, Ana Marija Gjurovic, Elmas Malvolti, Navdeep Tangri
Chronic kidney disease (CKD) affects more than one in ten people worldwide. However, results from the REVEAL-CKD study suggest that it is often not diagnosed. Many patients are therefore unaware that they have CKD, putting them at increased risk of disease progression and complications. Empowering patients with knowledge about CKD will allow them to become active participants in their own care, driving improvements in diagnosis rates and changing patient outcomes for the better. In this article, we provide patient and clinician perspectives on the importance of early CKD diagnosis and management...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38443645/satisfaction-with-the-injection-experience-of-a-new-citrate-free-formulation-of-ixekizumab
#56
JOURNAL ARTICLE
Sanjay Chabra, Julie Birt, Rebecca Bolce, Jeffrey Lisse, William N Malatestinic, Baojin Zhu, Miriam Kimel, Julie McCormack, Marissa Stefan, W Chad Cragun
INTRODUCTION: A new, citrate-free ixekizumab formulation, which is bioequivalent to the original formulation, was associated with significant reduction in injection site pain. This study evaluates patient satisfaction with the first injection experience of citrate-free ixekizumab in a real-world setting. METHODS: A non-interventional, observational, web-based survey of adults (≥ 18 years) with psoriasis, psoriatic arthritis, or axial spondyloarthritis was conducted between August 2022 and March 2023...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38430403/correction-to-association-of-patient-satisfaction-with-cataract-grading-in-five-types-of-multifocal-iols
#57
Sana Niazi, Zisis Gatzioufas, Sorcha N Dhubhghaill, Majid Moshirfar, Amir Faramarzi, Farzad Mohammadi, Bahar Kheiri, Alireza Peyman, Mohammad Heidari, Farideh Doroodgar
No abstract text is available yet for this article.
March 2, 2024: Advances in Therapy
https://read.qxmd.com/read/38430402/treatment-patterns-with-mirabegron-and-antimuscarinics-for-overactive-bladder-a-prospective-registry-study-in-taiwan-and-south-korea-faith
#58
JOURNAL ARTICLE
Seung-June Oh, Sung Tae Cho, Hann-Chorng Kuo, Eric Chieh-Lung Chou, Yu-Chao Hsu, Kyu-Sung Lee, Farid Hadi, Yi Song, Budiwan Sumarsono
INTRODUCTION: This study aimed to assess overactive bladder (OAB) treatment patterns and factors associated with effectiveness and persistence. METHODS: A prospective, longitudinal, observational registry study of adults starting OAB therapy with mirabegron or antimuscarinics was undertaken. Primary endpoints were time from treatment initiation to discontinuation/switching; proportion who discontinued/switched; and reasons for discontinuation/switching. Secondary endpoints included OAB Symptom Score (OABSS), OAB Questionnaire: Short Form, and OAB Bladder Assessment Tool scores; factors associated with effectiveness and persistence; and safety...
March 2, 2024: Advances in Therapy
https://read.qxmd.com/read/38427220/projected-impact-of-omidubicel-onlv-on-racial-ethnic-disparities-in-allogeneic-hematopoietic-cell-transplantation-allo-hct-outcomes-in-hematologic-malignancies
#59
JOURNAL ARTICLE
Nandita Khera, Marie Louise Edwards, Yan Song, Rochelle Sun, Rocio Manghani, Heayoung Shin, Ronit Simantov, James Signorovitch, Smitha Sivaraman, Usama Gergis
INTRODUCTION: In a phase III clinical trial (NCT02730299), omidubicel-onlv, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, showed rapid hematopoietic and immune recovery compared with standard umbilical cord blood (UCB) transplant across all racial/ethnic groups. METHODS: A decision-tree model was used to project the effect of omidubicel-onlv availability on addressing health disparities in allogeneic hematopoietic cell transplantation (allo-HCT) access and outcomes for patients with hematologic malignancies...
March 1, 2024: Advances in Therapy
https://read.qxmd.com/read/38421558/identification-of-a-group-of-therapeutic-targets-and-prognostic-biomarker-for-triple-negative-breast-cancer
#60
JOURNAL ARTICLE
Yan Li, Shengjie Yang, Lu Qi, Yinjuan Li, Xinghe Wang
INTRODUCTION: Triple-negative breast cancer (TNBC) is a highly heterogeneous disease. Mining differentially expressed genes of TNBC is helpful to explore new therapeutic targets. This study aimed to investigate diagnostic biomarker genes in TNBC compared to normal tissue. Additionally, we explored the functions and prognostic value of these key genes as well as potential targeted drugs that could affect these genes. METHODS: Differential gene expression analysis was conducted using the R software with data from the Gene Expression Omnibus (GEO) database...
February 29, 2024: Advances in Therapy
journal
journal
29381
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.